LCM Capital Management Inc Increases Stake in Amarin Co. plc (NASDAQ:AMRN)

LCM Capital Management Inc boosted its stake in Amarin Co. plc (NASDAQ:AMRN) by 3.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 838,259 shares of the biopharmaceutical company’s stock after buying an additional 25,100 shares during the period. LCM Capital Management Inc’s holdings in Amarin were worth $407,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Algert Global LLC purchased a new position in shares of Amarin in the 2nd quarter valued at approximately $34,000. China Universal Asset Management Co. Ltd. raised its holdings in Amarin by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 29,992 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Amarin by 8.8% during the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after buying an additional 104,939 shares during the period. Arkfeld Wealth Strategies L.L.C. boosted its holdings in shares of Amarin by 52.6% during the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 20,000 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS grew its position in shares of Amarin by 80.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 42,700 shares during the period. 22.25% of the stock is owned by institutional investors.

Amarin Stock Up 3.2 %

Shares of AMRN opened at $0.57 on Thursday. Amarin Co. plc has a 52 week low of $0.43 and a 52 week high of $1.36. The stock has a market cap of $233.06 million, a P/E ratio of -6.31 and a beta of 1.83. The business’s 50 day moving average price is $0.52 and its 200-day moving average price is $0.58.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Amarin from a “hold” rating to a “sell” rating in a research report on Friday, January 24th.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.